Art Morales on data, the placebo effect and the future of clinical trials

Art Morales is the CTO at Analgesic Solutions, a clinical research company focused on the conduct of clinical trials in pain. I caught up with Art to try and understand how emerging technologies like data, AI and algorithms will impact the way we both research and test new medicines in the future. One of the most interest areas of innovation is the cross pollination of ideas and frameworks from one industry to other. To that end, Art and his team are bringing in concepts from manufacturing and statistical process control to monitor and improve the effectiveness of clinical trials for pain medication. Upon completing his Ph.D. with Dr. Paul Schimmel at Massachusetts Institute of Technology (MIT), Art started his career with Genome Therapeutics as a Senior Computational Biologist. He subsequently led a variety of teams at various companies including the Novartis Institutes for Biomedical Research, where he was Global lead for Biology Platform Informatics.